Unity Biotechnology
Yahoo Finance • 2 years ago
10 Penny Stocks That Will Make You A Millionaire
In this article, we will discuss the 10 penny stocks that will make you a millionaire. If you want to explore similar stocks, you can also take a look at 5 Penny Stocks That Will Make You A Millionaire. Penny stocks can be an attractive o... Full story
Yahoo Finance • 2 years ago
UNITY Biotechnology, Inc. Reports Third Quarter 2022 Financial Results and Business Updates
Unity Biotechnology, Inc. - Announced positive 24-week data in Phase 2 BEHOLD Study of UBX1325 in Patients with Diabetic Macular Edema; single injection led to statistically significant and clinically meaningful improvement in BCVA with f... Full story
Yahoo Finance • 2 years ago
UNITY Biotechnology to Host Program Update on BEHOLD, the Phase 2 Clinical Trial of UBX1325 in Patients with Diabetic Macular Edema
SOUTH SAN FRANCISCO, Calif., Oct. 31, 2022 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY” or the “Company”) (Nasdaq:UBX), a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announce... Full story
Yahoo Finance • 2 years ago
UNITY Biotechnology Announces Reverse Stock Split Effective at 5:00 PM Eastern Time Today
SOUTH SAN FRANCISCO, Calif., Oct. 19, 2022 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY” or the “Company”) (Nasdaq:UBX), a biotechnology company developing therapeutics to slow, halt or reverse diseases of aging, today announced... Full story
Yahoo Finance • 2 years ago
UNITY Biotechnology’s Investor and Analyst Day to Highlight UBX1325 Program in Age-Related Diseases of the Eye
- Presentations from UNITY’s leadership team and fireside chat with retina expert Robert B. Bhisitkul, M.D., Ph.D., on Wednesday, October 12 from 8:00 a.m. to 9:30 a.m. ET - SOUTH SAN FRANCISCO, Calif., Oct. 11, 2022 (GLOBE NEWSWIRE) --... Full story
Yahoo Finance • 2 years ago
UNITY Biotechnology to Participate in Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., Aug. 31, 2022 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (Nasdaq: UBX), a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that members of its seni... Full story
Yahoo Finance • 2 years ago
UNITY Biotechnology Announces Pricing of Upsized Underwritten Public Offering
SOUTH SAN FRANCISCO, Calif., Aug. 17, 2022 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) (Nasdaq:UBX), a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced the pricing of... Full story
Yahoo Finance • 2 years ago
UNITY Biotechnology Announces Proposed Public Offering of Common Stock
SOUTH SAN FRANCISCO, Calif., Aug. 16, 2022 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) (Nasdaq:UBX), a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that it has com... Full story
Yahoo Finance • 2 years ago
UNITY Biotechnology to Present Clinical Data at the American Society of Retina Specialists (ASRS) 40th Annual Scientific Meeting
SOUTH SAN FRANCISCO, Calif., July 12, 2022 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that 24-week c... Full story
Yahoo Finance • 2 years ago
UNITY Biotechnology Reports Granting of New Employment Inducement Award
SOUTH SAN FRANCISCO, Calif., June 29, 2022 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that from June... Full story
Yahoo Finance • 2 years ago
UNITY Biotechnology Announces Appointment of Accomplished Finance and Operations Executive Michael Samar to the Board of Directors
SAN FRANCISCO, May 26, 2022 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that Michael Samar, current c... Full story
Yahoo Finance • 3 years ago
UNITY Biotechnology to Participate in the UBS 2022 Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., May 25, 2022 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (Nasdaq: UBX), a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that members of its senio... Full story
Yahoo Finance • 3 years ago
UNITY Biotechnology, Inc. Reports First Quarter 2022 Financial Results and Business Updates
-Completed enrollment in BEHOLD, the Phase 2 clinical trial of UBX1325 in DME; BEHOLD remains on track with 12-week safety and efficacy data anticipated by mid-year 2022- -Dosed first patient in ENVISION, the Phase 2 clinical trial of UBX... Full story
Yahoo Finance • 3 years ago
UNITY Biotechnology Presentations at ARVO 2022 Showcase UBX1325 as an Investigational Novel Therapeutic Modality for Retinal Vascular Diseases
SOUTH SAN FRANCISCO, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, announced presentations at the... Full story
Yahoo Finance • 3 years ago
UNITY Biotechnology to Present Clinical Data at the Association for Research in Vision & Ophthalmology (ARVO) 2022 Annual Meeting
SOUTH SAN FRANCISCO, Calif., April 21, 2022 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that clinical... Full story
Yahoo Finance • 3 years ago
UNITY Biotechnology Doses First Patient in ENVISION, the Phase 2 Study of UBX1325 in Wet Age-Related Macular Degeneration
SOUTH SAN FRANCISCO, Calif., April 19, 2022 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that the firs... Full story
Yahoo Finance • 3 years ago
UNITY Biotechnology Completes Enrollment in BEHOLD, the Phase 2 Study of Senolytic Candidate UBX1325 in Diabetic Macular Edema
12-week safety and efficacy data anticipated by mid-year 2022 24-week safety and efficacy data anticipated before year-end 2022 SOUTH SAN FRANCISCO, Calif., April 12, 2022 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ... Full story
